Patrick Durez
Brussels
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Patrick Durez
Spatial and functional characterization of ER stress proteins links fibroblast plasticity and proliferative processes in human osteoarthritic synovitis
Abstract A strong crosstalk exists between endoplasmic reticulum (ER) stress and synovitis. Beyond their canonical role in protein folding, ER stress chaperones may promote inflammation, cell survival, and fibroblast activation under pathological conditions.
The relationship between clinical disease activity, synovial inflammatory profile, and treatment response in rheumatoid arthritis
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database http://orcid.org/0000-0001-7766-6167Peter C Taylor1, http://orcid.org/0000-0003-1111-8218Tsutomu Takeuchi2, http://orcid.org/0000-0001-7518-1131Gerd R Burmester3, Patrick Durez4, Josef S Smolen5, Walter Deberdt6, Maher Issa6, Jorge Ross Terres6, Natalia Bello6, http://orcid.org/0000-0002-3892-6947Kevin L...
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database http://orcid.org/0000-0001-7766-6167Peter C Taylor1, http://orcid.org/0000-0003-1111-8218Tsutomu Takeuchi2, http://orcid.org/0000-0001-7518-1131Gerd R Burmester3, Patrick Durez4, Josef S Smolen5, Walter Deberdt6, Maher Issa6, Jorge Ross Terres6, Natalia Bello6, http://orcid.org/0000-0002-3892-6947Kevin L...
Onset of IgA nephropathy in a patient treated with infliximab for ankylosing spondylitis
Onset of IgA nephropathy in a patient treated with infliximab for ankylosing spondylitis Charlotte Anne Baert1, Selda Aydin1, Philippe Leroy2 and http://orcid.org/0000-0002-7156-2356Patrick Durez1 1Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium 2Department of Nephrology, CHR Mons-Hainaut, Mons, Hainaut, Belgium Correspondence to Professor Patrick Durez; patrick.durez{at}uclouvain.be Abstract We report the case of a 43-year-old man, suffering from ankylosing spondylitis...
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial
Summary Background Although targeted biological treatments have transformed the outlook for patients with rheumatoid arthritis, 40% of patients show poor clinical response, which is mechanistically still unexplained. Because more than 50% of patients with rheumatoid arthritis have low or absent CD20 B cells—the target for rituximab—in the main disease tissue (joint synovium), we hypothesised that, in these patients, the IL-6 receptor inhibitor tocilizumab would be more effective.
Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review
Abstract Baricitinib is an oral selective inhibitor of Janus kinase (JAK)1 and JAK2 that has proved effective and well tolerated in the treatment of rheumatoid arthritis (RA) in an extensive programme of clinical studies of patients with moderate-to-severe disease.
Tapering biological DMARDs in patients with low RA disease activity achievable in daily practice
Dose reduction of biological DMARDs in patients with rheumatoid arthritis who have achieved low disease activity is a feasible goal in daily practice, according to data published in Arthritis Research & Therapy. “A significant proportion of RA patients achieve low disease activity or remission when treated with a biological DMARD,” Patrick Durez, MD, of the Catholic University of Louvain, in Brussels, Belgium, told Healio Rheumatology.
Severe panniculitis and polyarthritis caused by acinar cell carcinoma arising from an ectopic pancreas
The pancreatitis, panniculitis and polyarthritis (PPP) syndrome is a rare condition caused by pancreatic diseases, such as acute or chronic pancreatitis or pancreatic carcinoma. We report the first case of PPP syndrome caused by metastatic acinar cell carcinoma from an ectopic pancreas. The symptoms were successfully managed by the treatment of the metastatic carcinoma. Pancreatic cytosteatonecrosis should be always considered in a patient who is showing symptoms of panniculitis and polyarthritis.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Patrick
Contact Patrick, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack